About Psyzone Research
A scientific evidence platform dedicated to psychedelic-assisted therapies
Our Mission
Psyzone Research is dedicated to bridging the gap between scientific research and public understanding of psychedelic-assisted therapies. We believe that evidence-based information should be accessible to everyone—researchers, clinicians, patients, and the general public.
Our platform aggregates, analyzes, and presents peer-reviewed research on substances like psilocybin, MDMA, ketamine, and other psychedelics, focusing on their therapeutic potential for conditions such as depression, PTSD, anxiety, and addiction.
How It Works
Daily Discovery
We continuously scan PubMed, Crossref, ClinicalTrials.gov, and other sources to discover new research papers on psychedelic therapies.
AI-Powered Analysis
Each paper undergoes structured analysis using advanced AI to extract key findings, methodology details, and clinical implications.
Human Oversight
Our editorial team reviews and validates each analysis before publication, ensuring accuracy and appropriate context.
Our Scoring System
Transparent methodology for evaluating research quality
AI Analysis Score
Quality assessment of methodology, sample size, outcomes, and statistical rigor.
Clinical Impact Score
Assessment of real-world clinical relevance and consensus within the medical community.
Evidence Level
Based on standardized evidence hierarchies (systematic reviews = highest, case reports = lowest).
Evidence Level Definitions
Editorial Independence
We maintain strict editorial independence. Our analysis is not influenced by pharmaceutical companies, clinics, or advocacy groups. We present evidence objectively, including limitations and potential risks.
Global Accessibility
Our summaries are available in multiple languages (English, Portuguese, Spanish) to make scientific information accessible to diverse communities worldwide.
Get in Touch
For questions, feedback, or to report issues with our content, please contact us at: